FlandersBio on Twitter

Follow us on Twitter

Archive for March 2011 - News

Archive for March 2011 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Devgen nv successfully completes a private placement for a total amount of € 26.8 million

31.03.2011

Today, Devgen nv placed 4,584,549 new shares in a private placement with pre-identified investors for a total amount of € 26,819,611. The shares were placed at a price of € 5.85 per share, which is at least equal to the 30 day average price, in compliance with Belgian Company Law. read more

Stamcellen, een antwoord op stralingsziekte? Cryo-Save biedt Japan opslag van stamcellen aan

30.03.2011

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', ‘de Groep’), de toonaangevende internationale familie-stamcelbank, biedt Japan de opslag van autologe, volwassen stamcellen aan. Japan wil preventief stamcellen opslaan van de reddingswerkers die in de kerncentrale van Fukushima aan hoge straling zullen worden blootgesteld. Recente wetenschappelijke studies tonen aan dat stamcellen de schade door hoge radioactieve straling kunnen herstellen. Japan vreest een tekort aan opslagcapaciteit en vraagt hulp. Tegelijkertijd opent dit de discussie of een dergelijke preventieve en potentieel levensreddende maatregel niet ter beschikking moet komen van alle werknemers in kerncentrales? read more

Galapagos increases share capital through warrant exercises

30.03.2011

Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee warrant exercises. read more

Cancer is a protein aggregation disease

28.03.2011

Protein aggregation, generally associated with Alzheimer’s and mad cows disease, turns out to play a significant role in cancer. In a paper published in Nature Chemical Biology, Frederic Rousseau and Joost Schymkowitz, both of VIB, Vrije Universiteit Brussel and K.U.Leuven describe that certain mutations of p53, an important tumor suppressor, cause the protein to misfold in a way that the proteins start to aggregate. This not only disrupts the protective function of normal p53, but of other related proteins as well. read more

Ablynx initiates Phase I/II trial for ALX-0061 (anti-IL-6R) in patients with Rheumatoid Arthritis

28.03.2011

Ablynx [Euronext Brussels: ABLX] announced today that it had initiated a double-blind, randomised, placebo-controlled Phase I/II study with ALX-0061, a Nanobody targeting the interleukin 6 receptor (IL-6R), in patients with rheumatoid arthritis (RA). read more

QUINVITA issues one of the first professional Jatropha curcas plantation manuals

28.03.2011

The industrial crop technology company, QUINVITA, today announced at the World Biofuels Markets conference in Rotterdam, the Netherlands, the launch of one of the first professional Jatropha curcas plantation manuals. This document is summarizing in a systematic way all the knowledge needed to successfully plant, cultivate and harvest larger scale Jatropha curcas plantations. read more

QUINVITA launches two new cultivars in its QUINVITA PRO (QVP) seed product portfolio

28.03.2011

The Industrial Crops Technology Company, QUINVITA announces today the selection of two new cultivars in the QUINVITA PRO (QVP) seeds product portfolio: QVP 1003 and QVP 1064. Both these cultivars have been selected in the global breeding program of QUINVITA on the basis of high performance for several yield components of Jatropha curcas (oil content, fruits per bunch, bunches per season). QVP 1003 and QVP 1064 have entered the QUINVITA product placement trial network and the QVP seed production program. Seed of these cultivars will be available for preferred customers of QUINVITA for the 2011-2012 planting seasons. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print